XTL Biopharmaceuticals (XTLB)
(Real Time Quote from BATS)
$2.50 USD
+0.08 (3.22%)
Updated Apr 29, 2024 12:04 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
XTLB 2.50 +0.08(3.22%)
Will XTLB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for XTLB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for XTLB
12 Health Care Stocks Moving In Monday's Pre-Market Session
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
XTL Biopharmaceuticals Regains Nasdaq Compliance
12 Health Care Stocks Moving In Wednesday's Intraday Session
OCGN, DNMR and DERM are among pre market gainers